Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18241979 | 0.84 | GABRA1 (0.43) | GABRA1GABRB2ADRA2AADRA2BADRA2C | |
| SCHEMBL9734348 | 0.82 | GABRA1 (0.50) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL10334968 | 0.82 | GABRA1 (0.56) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL18378614 | 0.81 | GABRA1 (0.50) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL18242390 | 0.81 | CYSLTR2 (0.40) | GABRA1GABRB2CYP2D6 | |
| SCHEMBL23735841 | 0.78 | GABRA1 (0.46) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL18242436 | 0.78 | GABRA1 (0.52) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL18843526 | 0.78 | GABRA1 (0.52) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL21736785 | 0.78 | GABRA1 (0.52) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL10334969 | 0.75 | LMNA (0.59) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | GABRA1 924/4885GABRB2 2041/4885LMNA 2963/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | GABRA1 924/4885GABRB2 2041/4885LMNA 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.